NCT03101644View on ClinicalTrials.gov

Optimization of Darunavir Therapy and Dosage Recommendations

PHASE4CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

June 12, 2019

Study Completion Date

June 12, 2019

Conditions
Human Immunodeficiency Virus I Infection
Interventions
DRUG

Darunavir

The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)

Trial Locations (1)

1200

Cliniques universitaires Saint-Luc, Brussels

All Listed Sponsors
collaborator

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

lead

Université Catholique de Louvain

OTHER

NCT03101644 - Optimization of Darunavir Therapy and Dosage Recommendations | Biotech Hunter | Biotech Hunter